Liraglutide Research: The Once-Daily GLP-1 Analogue and What Its Trials Investigated

What is liraglutide (NN2211)?

What is liraglutide? It is an acylated analogue of human glucagon-like peptide-1, developed at Novo Nordisk and appearing in the early clinical literature under the code NN2211. Structurally it is GLP-1 with one amino-acid substitution — arginine at position 34, which forces the acylation to happen at a single defined site — and a C16 palmitate attached at lysine 26 through a gamma-glutamate linker (Knudsen and Lau, 2019).

It is the active molecule in approved prescription products for type 2 diabetes and for weight management. That is a factual identification, offered without benefit framing, and regulatory status has its own section below. What is supplied as a research material is a laboratory synthetic in lyophilized powder form — not the marketed medicine, not equivalent to it, and not for human use.

Discovery: the structure–activity study that started the class

Liraglutide is unusual among the compounds in the research library in that the paper explaining why it looks the way it does is publicly readable and genuinely instructive. Knudsen et al. (2000, J Med Chem, PMID 10794683) reported a series of fatty-acid derivatives of GLP-1 and the structure–activity relationship that emerged from them. The findings, stated as the paper states them:

• Native GLP-1 had a potency (EC₅₀) of 55 pM at the cloned human GLP-1 receptor, and many derivatives retained similar or higher potency despite carrying large substituents.
• All compounds derivatised with fatty acids of twelve carbons or longer were markedly protracted compared with GLP-1 — the observation that made a once-daily analogue possible at all.
• The trade-off was explicit: the longer the fatty acid, the more potency was lost. Attaching two fatty-acid substituents caused considerable loss of potency, and modifying the N-terminus for metabolic stability interfered with acylation.

C16 palmitate with a gamma-glutamate linker was the combination selected. Knudsen and Lau (2019) later revisited that decision in a single review covering both this molecule and semaglutide — the clearest statement anywhere that the two are one lineage rather than two competing products. The semaglutide programme kept the strategy and changed the parameters: a longer diacid, a different linker, and an extra substitution for protease resistance.

Reference data

The facts below are drawn from the public chemical record (PubChem CID 16134956) and the primary literature. Fields that could not be sourced are omitted rather than estimated.

That half-life figure is the most informative number on this page. Agersø et al. measured it in a double-blind, randomised, dose-escalation study in healthy male subjects with 84-hour sampling. Reported strictly as a measured molecule property, carrying no dosing implication — and, in one number, the reason this molecule and the once-weekly analogues sit in different generations.

Mechanism — single-receptor agonism plus albumin binding

The mechanism is the simplest in this cluster, and each line is what researchers characterised in model systems rather than an effect in any reader:

• GLP-1 receptor (GLP-1R) — the only receptor liraglutide is designed to engage. It is a mono-agonist, like semaglutide and unlike tirzepatide, survodutide, mazdutide or retatrutide.
• Albumin binding via the acyl chain — Knudsen et al. state the purpose of derivatisation directly: the compounds were derivatised with fatty acids in order to protract their action by facilitating binding to serum albumin. This is a pharmacokinetic mechanism, not a signalling one.
• An acknowledged potency cost — the same paper records that acylation trades receptor potency for duration. That honest trade-off is visible again a generation later, where semaglutide’s discovery paper reports GLP-1R affinity roughly three-fold lower than liraglutide’s alongside higher albumin affinity.

Liraglutide also appears in this catalogue’s literature from an unexpected direction: it was the active comparator in the phase 2 dose-finding trial of the amylin analogue cagrilintide, which is how a 2000-vintage design ends up as the benchmark in a 2021 trial of a different hormone family. The cross-class receptor comparison itself lives on the comparison page and is not restated here.

What the LEAD, LEADER and SCALE programmes investigated

Because liraglutide reached clinical development a decade before the once-weekly agonists, its trial literature is both older and longer-running. Read strictly as what each study examined:

LEAD (type 2 diabetes)

• Garber et al., 2009 (Lancet, PMID 18819705) — LEAD-3 Mono, a 52-week phase 3 double-blind parallel-treatment trial comparing liraglutide monotherapy with glimepiride, a sulfonylurea.
• Buse et al., 2009 (Lancet, PMID 19515413) — LEAD-6, a 26-week randomised open-label trial comparing once-daily liraglutide with twice-daily exenatide. This one is historically interesting as an early head-to-head between two GLP-1 receptor agonists rather than against an older drug class.

LEADER (cardiovascular outcomes)

• Marso et al., 2016 (NEJM, PMID 27295427) — LEADER, which investigated cardiovascular outcomes in people with type 2 diabetes. It was published in the same year as SUSTAIN-6 for semaglutide, and the two are the reason this class has cardiovascular-outcome data at all.

SCALE (weight management)

• Pi-Sunyer et al., 2015 (NEJM, PMID 26132939) — a randomised controlled trial of liraglutide 3.0 mg in weight management, the anchor publication of the SCALE programme and the study that established a separate indication pathway later followed by the once-weekly molecules.

No outcome figures from any of these appear here. This page records what was investigated, in whom, and by whom.

Evidence status, regulatory status, and what is not established

What is established: an unusually complete public chain of evidence, from a published structure–activity study through first-in-human pharmacokinetics to phase 3 trials, cardiovascular outcomes and more than a decade of post-marketing use. Among the compounds in this catalogue, that is close to a best case.

Liraglutide is also an approved prescription medicine in many jurisdictions, in separate products for type 2 diabetes and for weight management, and reached market well before any once-weekly agonist in this cluster — stated as a matter of public record. Compare cagrilintide and survodutide, still investigational, and mazdutide, whose approval is jurisdiction-specific.

What is not established, and is deliberately not claimed here: none of that says anything about a research-grade powder. The trials used a manufactured, regulated pharmaceutical administered under medical supervision in monitored populations, and their findings do not transfer to laboratory material or to any reader. A long safety record and an approval both belong to a specific product and a specific regulated supply chain, not to a molecule name. This page reports no outcome, makes no efficacy or benefit claim, gives no dosing guidance, and describes material that is not for human or veterinary use.

How to verify this compound yourself

Identity and purity rest on two orthogonal analytical methods, both reported on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of the chromatogram. The palmitoyl chain makes liraglutide considerably more hydrophobic than unmodified GLP-1, so a des-acyl impurity is well separated rather than hidden under the main peak.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 3751 Da). Liraglutide is the lightest peptide in this cluster by several hundred daltons, which makes it one of the easier ones to distinguish from its relatives on mass alone.
• Endotoxin / sterility — where tested, separate quality attributes reported independently of chemical purity.

See how to read a COA for what each certificate line means and how to verify peptide purity for how HPLC and mass spec fit together. Check the exact batch on the self-serve verify tool, and read how to spot a fake COA before trusting any certificate.

Research-grade sourcing and verification

Liraglutide is not held in Cellworks stock. It appears in the sourcing catalogue as available to order: our supplier lists it, we have not bought it, and sourcing takes roughly two to three weeks. No price is quoted until availability is confirmed, and there is no cart button for it.

Anything sourced this way is a laboratory research reagent with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spectrometry identity. It is not the approved medicine and is not for human use.

Frequently asked questions

Literature cited

1. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. “Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.” J Med Chem. 2000;43(9):1664–1669. PMID 10794683. pubmed.ncbi.nlm.nih.gov/10794683.
2. Agersø H, Jensen LB, Elbrønd B, et al. “The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.” Diabetologia. 2002;45(2):195–202. PMID 11935150. pubmed.ncbi.nlm.nih.gov/11935150.
3. Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Front Endocrinol (Lausanne). 2019;10:155. PMID 31031702. pubmed.ncbi.nlm.nih.gov/31031702.
4. Garber A, Henry R, Ratner R, et al. “Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.” Lancet. 2009;373(9662):473–481. PMID 18819705. pubmed.ncbi.nlm.nih.gov/18819705.
5. Buse JB, Rosenstock J, Sesti G, et al. “Liraglutide once a day versus exenatide twice a day for type 2 diabetes (LEAD-6): a 26-week randomised, parallel-group, multinational, open-label trial.” Lancet. 2009;374(9683):39–47. PMID 19515413. pubmed.ncbi.nlm.nih.gov/19515413.
6. Marso SP, Daniels GH, Brown-Frandsen K, et al. “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” (LEADER) N Engl J Med. 2016;375(4):311–322. PMID 27295427. pubmed.ncbi.nlm.nih.gov/27295427.
7. Pi-Sunyer X, Astrup A, Fujioka K, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” (SCALE) N Engl J Med. 2015;373(1):11–22. PMID 26132939. pubmed.ncbi.nlm.nih.gov/26132939.
8. National Center for Biotechnology Information. “PubChem Compound Summary for CID 16134956, Liraglutide.” pubchem.ncbi.nlm.nih.gov/compound/16134956 (formula, mass, CAS 204656-20-2).